Advertisement

Picture EBD Group BIO-Europe Spring 2026 Lisbon to 20 Mar 650x100px
Organisation › Details

NeoGenomics (Group)

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and Phoenix, Arizona; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. *

 

Period Start 2017-03-13 renamed before
Product Industry diagnostic services
     
  Street 12701 Commonwealth Drive
Suite 9
  City 33913 Fort Myers, FL
  Tel +1-239-768-0600
    Address record changed: 2024-01-05
     
Basic data Employees F: 1,001 to 5,000 (2021-12-31)
  Currency USD
  Annual sales 484,329,000 (revenue, net, total, consolidated (2021) 2021-12-31)
  Profit -8,347,000 (2021-12-31)
  Cash 316,827,000 (2021-12-31)
     
    * Document for »About Section«: NeoGenomics, Inc.. (5/9/22). "Press Release: NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary". Ft. Myers, FL.
     
   
Record changed: 2023-07-10

Advertisement

Picture EBD Group BIO-Europe Spring 2026 Lisbon to 20 Mar 650x200px

More documents for NeoGenomics (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2026 Shanghai to 03 Apr 650x300px




» top